Adam Pavlicek
Overview
Explore the profile of Adam Pavlicek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Andersson P, Burel S, Estrella H, Foy J, Hagedorn P, Harper Jr T, et al.
Nucleic Acid Ther
. 2025 Feb;
35(1):16-33.
PMID: 39912803
Hybridization-dependent off-target (OffT) effects, occurring when oligonucleotides bind via Watson-Crick-Franklin hybridization to unintended RNA transcripts, remain a critical safety concern for oligonucleotide therapeutics (ONTs). Despite the importance of OffT assessment...
2.
Lohaj O, Paralic J, Pella Z, Pella D, Pavlicek A
Diagnostics (Basel)
. 2024 May;
14(9).
PMID: 38732332
The focus of this study, and the subject of this article, resides in the conceptually funded usability evaluation of an application of descriptive models to a specific dataset obtained from...
3.
Hallin J, Bowcut V, Calinisan A, Briere D, Hargis L, Engstrom L, et al.
Nat Med
. 2022 Oct;
28(10):2171-2182.
PMID: 36216931
Recent progress in targeting KRAS has provided both insight and inspiration for targeting alternative KRAS mutants. In this study, we evaluated the mechanism of action and anti-tumor efficacy of MRTX1133,...
4.
Briere D, Li S, Calinisan A, Sudhakar N, Aranda R, Hargis L, et al.
Mol Cancer Ther
. 2021 Mar;
20(6):975-985.
PMID: 33722854
KRAS inhibitors, including MRTX849, are promising treatment options for KRAS-mutant non-small cell lung cancer (NSCLC). PD-1 inhibitors are approved in NSCLC; however, strategies to enhance checkpoint inhibitor therapy (CIT) are...
5.
Hallin J, Engstrom L, Hargis L, Calinisan A, Aranda R, Briere D, et al.
Cancer Discov
. 2019 Oct;
10(1):54-71.
PMID: 31658955
Despite decades of research, efforts to directly target KRAS have been challenging. MRTX849 was identified as a potent, selective, and covalent KRAS inhibitor that exhibits favorable drug-like properties, selectively modifies...
6.
Lee E, Valencia T, Allerson C, Schairer A, Flaten A, Yheskel M, et al.
Nat Commun
. 2019 Sep;
10(1):4148.
PMID: 31515477
Autosomal dominant polycystic kidney disease (ADPKD), caused by mutations in either PKD1 or PKD2 genes, is one of the most common human monogenetic disorders and the leading genetic cause of...
7.
Huang X, Magnus J, Kaimal V, Karmali P, Li J, Walls M, et al.
Mol Cancer Ther
. 2017 Feb;
16(5):905-913.
PMID: 28167506
Hepatocellular carcinoma (HCC) is one of the most common human malignancies with poor prognosis and urgent unmet medical need. Aberrant expression of multiple members of the miR-17 family are frequently...
8.
Van der Ree M, de Vree J, Stelma F, Willemse S, Van Der Valk M, Rietdijk S, et al.
Lancet
. 2017 Jan;
389(10070):709-717.
PMID: 28087069
Background: miR-122 is an important host factor for hepatitis C virus (HCV) replication. The aim of this study was to assess the safety and tolerability, pharmacokinetics, and antiviral effect of...
9.
Wagenaar T, Zabludoff S, Ahn S, Allerson C, Arlt H, Baffa R, et al.
Mol Cancer Res
. 2015 Mar;
13(6):1009-21.
PMID: 25758165
Unlabelled: Hepatocellular carcinoma (HCC) remains a significant clinical challenge with few therapeutic options available to cancer patients. MicroRNA 21-5p (miR-21) has been shown to be upregulated in HCC, but the...
10.
Di Narzo A, Tejpar S, Rossi S, Yan P, Popovici V, Wirapati P, et al.
J Natl Cancer Inst
. 2014 Sep;
106(10).
PMID: 25246611
Background: Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging system. We investigated if four well-documented gene expression risk scores can improve patient...